Floatz logo

Bitr2101

NHL

Boston Immune Technologies and TherapeuticsPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

410 Active assets in the NHL cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
PEGASPARGASE
Ciusss de L'Est de l'Île de Montréal
Phase 4BBB
Inno-206
National Cancer Institute (NCI)
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Mwanasha Merrill, MD
Phase 3BBB
Entecavir
Fudan University
Phase 4BBB

View all 50 →

Same molecule, other indications

Bitr2101 is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
41 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →